[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BIOHENG THERAPEUTICS US LLC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100598340","phase-1-a-study-of-ctd402-in-t-alllbl-patients-100598340",false,"NCT07070219","A Study of CTD402 in T-ALL\u002FLBL Patients","A Single-Arm, Open-Label, Multi-Center, Phase 1b\u002F 2 Study to Evaluate the Safety, Efficacy, and Cellular Pharmacokinetic Profile of CTD402 in Participants With Relapsed\u002FRefractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) (TENACITY-01)","TENACITY-01","Key Inclusion Criteria:\n\n1. Male or female, ≥ 12 years of age.\n2. Participants with body weight ≥ 40 kilogram.\n3. Relapsed or refractory T-ALL\u002FLBL is defined as one of the following:\n\n   1. Relapsed or refractory disease after two or more lines of systemic therapy;\n   2. The first relapse occurs within 12 months after first remission;\n   3. Relapse after allogeneic HSCT and must be ≥100 days from HSCT prior to screening period.\n4. The presence of bone marrow lymphoblasts is ≥ 5% as determined by morphologic evaluation or evidence of extramedullary disease at screening.\n5. Have eligible HLA-matched related donor (MRD) or unrelated donor (URD), eligible haploidentical donor (HID) or syngeneic donors.\n6. Adequate organ function\n7. Karnofsky PS ≥ 60 (for participants age ≥ 16) or Lansky PS ≥ 60 (for participants \\\u003C 16) at screening.\n\nKey Exclusion Criteria:\n\n1. Participants with concomitant genetic syndromes associated with bone marrow failure states or any other known bone marrow failure syndrome.\n2. Active central nervous system (CNS) involvement\n3. Participants with following cardiac conditions will be excluded:\n\n   1. History of heart failure New York Heart Association (NYHA) class III or IV;\n   2. History of myocardial infarction, cardiovascular angioplasty or stenting, unstable angina, or other serious heart diseases within 12 months of enrollment.\n4. Primary immune deficiency.\n5. Presence of uncontrolled infections.\n6. Known history of infection with the human immunodeficiency virus (HIV); hepatitis C virus and syphilis.\n7. Active or latent hepatitis B virus infection\n8. Epstein-Barr virus (EBV), Cytomegalovirus (CMV) DNA or IgM positive at screening.","ALL","12 Years",{"count":20,"type":21},54,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed\u002Frefractory T-ALL\u002FLBL patients.\n\nParticipants with relapsed\u002Frefractory T-ALL\u002FLBL over the age of 12 will be eligible to participate.\n\nParticipants will receive one infusion of CTD402 on Day 0 and will be evaluated for anti-tumor activity by an independent review committee based on the NCCN criteria for T-ALL and the Lugano 2014 criteria for T-LBL.\n\nPatients will be followed for up to 24 months in this study and will be required to enroll under a separate long term follow up protocol to be followed for up to 15 years.",[28,29],"Acute Lymphocytic Leukemia Refractory","Lymphoma, Lymphoblastic",[31,32],"CAR-T Therapy","relapsed\u002Frefractory","RECRUITING","2026-02-04",{"date":36,"type":37},"2026-02-05","ACTUAL",{"date":39,"type":37},"2025-10-07",{"date":41,"type":21},"2028-12-30",{"name":43,"class":44},"BIOHENG THERAPEUTICS US LLC","INDUSTRY",8,""]